“On February 16, 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for “IgE-mediated food allergy in certain adults and children one year or older for the reduction of allergic reactions, including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods. Patients who take Xolair must continue to avoid foods they are allergic to. Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.”
U.S. FDA Article